Article is more than five years old, has been archived and is no longer updated.

Health Board Suspends Use of Pandemrix Vaccine

The chief public health authority has suspended the use of the H1N1 flu vaccine Pandemrix, now believed to be related to cases of narcolepsy across Europe.

According to the State Agency of Medicines website, researchers now consider it probable that use of Pandemrix combined with some yet unidentified factors has caused a heightened incidence of narcolepsy in Finland.

In Estonia, use of Pandemrix has been less widespread than in other European countries, Maia Uusküla, drug safety director of the State Agency of Medicines, told ETV. According to her, there have been few reports of serious side effects. The two more serious cases have been allergy-related.

As of February 1, 10,300 people in Estonia had been vaccinated with Pandemrix.

Hea lugeja, näeme et kasutate vanemat brauseri versiooni või vähelevinud brauserit.

Parema ja terviklikuma kasutajakogemuse tagamiseks soovitame alla laadida uusim versioon mõnest meie toetatud brauserist: